Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.81% | -0.46% | 5.47% | -0.07% | 11.44% |
| Total Depreciation and Amortization | -5.45% | -63.39% | 21.86% | 99.51% | -0.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.82% | -30.73% | 32.57% | -20.76% | -12.24% |
| Change in Net Operating Assets | 111.18% | -7,623.28% | -88.80% | 122.19% | 66.20% |
| Cash from Operations | 29.17% | -69.37% | 9.90% | 22.81% | 33.11% |
| Capital Expenditure | -2,189.87% | 37.30% | -334.48% | 87.87% | 67.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -310.66% | 140.02% | 3,984.83% | -100.66% | 12.71% |
| Cash from Investing | -313.50% | 140.83% | 3,815.79% | -100.69% | 13.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 484.22% | 1,597.98% | -98.28% | 683.90% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 484.22% | 1,597.98% | -98.28% | 683.90% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.56% | 56.08% | -206.87% | 69.63% | 140.18% |